ReviewJournal of clinical research in pediatric endocrinology2017
A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty.
Review in Journal of clinical research in pediatric endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.Endocrine · 2025Pooled it
- Efficacy of combined gonadotropin-releasing hormone analogue and growth hormone therapy in girls with central precocious puberty: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Lipid profile in girls with precocious puberty: a systematic review and meta-analysis.BMC endocrine disorders · 2023Pooled it
- Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.The Journal of clinical endocrinology and metabolism · 2020Trial
- Real-World Adult Height Outcomes in Girls with Central Precocious Puberty Receiving GnRHa Monotherapy or Combined with Growth Hormone: A Cohort Study in China.Advances in therapy · 2026Article
- Rising incidence of central precocious puberty in Thailand: a nationwide population-based study before, during, and after the COVID-19 pandemic (2018-2024).Clinical and experimental pediatrics · 2026Article
- Mental Health of Youths Who Use Puberty Blockers.JAMA network open · 2026Article
- Use of serum MKRN3 and DLK1 levels in precocious puberty: association with an MKRN3 pathogenic variant.Therapeutic advances in endocrinology and metabolism · 2026Article
- Long-term clinical outcomes in females with precocious puberty treated with gonadotropin-releasing hormone analogues.Frontiers in endocrinology · 2026Article
- Automatic Bone Age Determination in Adult Height Prediction for Girls with Early Variants Puberty and Precocious PubertyJournal of clinical research in pediatric endocrinology · 2025Article
- Performance of adult height prediction methods in 6 to 8-year-old girls with GnRH-dependent precocious puberty.Journal of pediatric endocrinology & metabolism : JPEM · 2025Article
- The efficacy and safety of pharmacotherapy for girls with central precocious puberty or early normal puberty: a retrospective cohort study.Scientific reports · 2025Article
- Approach to premature thelarche in children.Singapore medical journal · 2025Article
- Long-Term Efficacy and Safety of Leuprorelin Treatment in Children with Central Precocious Puberty: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2025Review
- Precocious puberty: a comprehensive review of diagnosis and clinical presentation, etiology, and treatment.Asian biomedicine : research, reviews and news · 2025Article
- Efficacy and safety of different doses of gonadotropin-releasing hormone analogues in the treatment of precocious puberty in children: a systematic review and meta-analysis.Translational pediatrics · 2025Article
- Adult height in girls with idiopathic central precocious puberty treated with triptorelin.Frontiers in endocrinology · 2024Observational
- Confirming the association between low serum 25OHD levels in girls with central precocious puberty and its severity.BMC pediatrics · 2023Article
- Early Normal Puberty and Accelerated Puberty in Girls: How Can We Avoid Unnecessary Treatment and Identify Children Who Are Likely to Benefit from Gonadotropin-Releasing Hormone Agonist Treatment?Turkish archives of pediatrics · 2023Article
- Which method is more effective in predicting adult height in pubertal girls treated with gonadotropin-releasing hormone agonist?Hormones (Athens, Greece) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central precocious puberty (CPP) is a diagnosis that pediatric endocrinologists worldwide increasingly make in girls of age 6-8 years and is mostly idiopathic. Part of the reason for increasing referral and diagnosis is the perception among the doctors as well as the patients that treatment of CPP with long-acting gonadotropin-releasing hormon analogues (GnRHa) promote height of the child. Although, the timing and the tempo of puberty does influence statural growth and achieved adult height, the extent of this effect is variable depending on several factors and is modest in most cases. Studies investigating GnRHa treatment in girls with idiopathic CPP demonstrate that treatment is able to restore adult height compromised by precocious puberty. However, reports on untreated girls with precocious puberty demonstrate that some of these girls achieve their target height without treatment as well, thus, blurring the net effect of GnRHa treatment on height in girls with CPP. Clinical studies on treatment of girls with idiopathic CPP on adult stature suffers from the solid evidence-base due mainly to the lack of well-designed randomized controlled studies and our insufficiencies of predicting adult height of a child with narrow precision. This is particularly true for girls in whom age of pubertal onset is close to physiological age of puberty, which are the majority of cases treated with GnRHa nowadays. Heterogeneous nature of pubertal tempo (progressive vs. nonprogressive) leading to different height outcomes also complicates the interpretation of the results in both treated and untreated cases. This review will attemp to summarize and critically appraise available data in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.